Currently, intravenous administration of exogenous FVIII, either as prophylaxis or episodically to treat bleeding events, trauma, or surgical procedures, constitutes the gold standard in hemophilia A treatment [2,13,14,15]. This evidence concerns the gene F8 and hemophilia A.